SGLT2 inhibitors, a type of diabetes drug, are associated with a lower risk for gout than DPP-4 inhibitors, research suggests.

Click through for further details on this safety announcement

“Based on these findings, for patients with PsA with significant joint disease, but milder skin disease, certainly a JAK inhibitor could be the drug of choice,” say the researchers.

Tumor necrosis factor inhibitor use by pregnant women with well-controlled rheumatoid arthritis is associated with a reduced risk for having a child that is born small for gestational age, study findings indicate.

Following the results of the ORAL Surveillance trial, which demonstrated increased rates of adverse events in people taking JAK inhibitors, Victoria Ruffing provides guidance on how to talk to patients about the risks associated with these medications.

Treatment with TNF inhibitors is associated with a twofold increased risk for new-onset psoriasis compared with nonbiologic agents, suggest findings from a Danish cohort study.

A tapering treat-to-target strategy can lead to a large reduction in TNF inhibitor dose without impacting disease control in people with psoriatic arthritis or axial spondyloarthritis, study findings indicate.

There were 28 reported MACEs, including 11 in the JAK inhibitor group, and crude incidence rates per 100 patient–years were similar across the JAK inhibitor, TNF inhibitor, and csDMARD treatment groups, said Meissner, at 0.41, 0.45, and 0.26, respectively.

By comparison, COX-2 inhibitor treatment was associated with reduced spinal progression compared with non-selective NSAIDs.

Treatment with a fixed-dose combination of the novel BTK inhibitor elsubrutinib and the JAK inhibitor upadacitinib offers no additional benefit over upadacitinib alone for people with rheumatoid arthritis, suggest phase 2 trial results.

*in patients with an inadequate response or intolerance to at least one tumor necrosis factor inhibitor.

People with rheumatoid arthritis who switch from one JAK inhibitor to another following initial discontinuation have a higher drug retention rate than if they switch to a TNF inhibitor instead, Swiss research suggests.

FDA issues a safety communication announcing that boxed warnings for CV events, cancer, and death are required on JAK inhibitor labels.

Findings from a rheumatoid arthritis registry study suggest that the JAK inhibitor tofacitinib may have comparable real-world effectiveness to TNF inhibitors.

Predictive models incorporating baseline variables can predict short-term TNF inhibitor response with moderate to high accuracy in people with active ankylosing spondylitis, study findings indicate.

Adding a conventional DMARD to tumor necrosis factor inhibitor therapy is not associated with clinically relevant improvements in drug retention or remission rates in people with axial spondyloarthritis, research suggests.

Patients with rheumatoid arthritis may be at a greater risk for poor treatment responses if they are obese or underweight regardless of whether they are taking a tumor necrosis factor inhibitor or an alternative biologic, research indicates.

Findings from a proof-of-concept trial provide preliminary evidence to suggest that the JAK inhibitor baricitinib is well tolerated and may have efficacy for the treatment of relapsing giant cell arteritis.

Lee, Hyoun-Ah Kim, Chang-Hee Suh & Ju-Yang Jun Abstract Objectives This study aimed to analyse the clinical features and outcomes of and reasons for discontinuing tumour necrosis factor (TNF) inhibitor therapy in older patients with ankylosing spondylitis (AS).

Of these, 84 (37.7%) cases had never been exposed to a TNF inhibitor and 139 (62.3%) had current or prior exposure.